Healthcare

Nanomerics Reports Complete Dosing of the Last Volunteer in the OC134 SUNLIGHT Trial

LONDON, GB / ACCESSWIRE / January 9, 2025 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that it…

1 year ago

AI/ML Innovations Inc. Welcomes Industry Veterans to Board of Directors

Mark Orsmond, a highly respected business professional in Canadian Healthcare, Appointed Executive ChairMichael Nemirow Joins as Director, Bringing Decades of…

1 year ago

BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciencesMeet BioLizard’s…

1 year ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025…

1 year ago

FYR Appoints Chris Howlett to its Board of Directors

Appointment adds business, market and partner development expertise to FYR board Addition highlights FYR’s evolution into partner of choice for…

1 year ago

Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients

Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A…

1 year ago

Hydreight Technologies Provides Shareholder Update on 2024 Milestones and 2025 Vision

VANCOUVER, British Columbia and LAS VEGAS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV:…

1 year ago

Amwell® divests virtual psychiatric care business to Avel eCare in all-cash transaction

Divestment of Amwell Psychiatric Care intended to focus product portfolio on key growth initiatives Company reiterates guidance for 2024 BOSTON,…

1 year ago

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company…

1 year ago

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health…

1 year ago